Cannabis and Breastfeeding: What the Evidence Actually Says

Pharmacokinetics of Cannabinoids in Human Milk and Postpartum Recovery

Delta-9-tetrahydrocannabinol (THC) is lipophilic, meaning it has a high affinity for fat. Because human breast milk is rich in lipids, THC may accumulate within it. Concentrations in breast milk can reach levels 3 to 8 times higher than those measured in maternal plasma.

THC Sequestration and Adipose Storage

Unlike water-soluble substances, THC is not cleared from the mammary system quickly. It stores itself in your body’s adipose tissue, bleeding back into the bloodstream and milk supply over an extended timeline.

• Transfer Rate: Research indicates 0.8% to 2.5% of a maternal dose may transfer to the infant.
• Elimination Half-Life: For frequent users, THC can remain detectable in breast milk for up to six weeks after consumption ceases.
• Metabolic Immatureness: Infants lack the enzymatic pathways to process these compounds efficiently. During the first year of life, their CB1 receptors are sensitive to external stimulation, which may increase vulnerability to cannabinoid exposure.

Delivery Methods and Plasma Peaks

The method of consumption dictates how long a substance remains in your system and, by extension, your milk.

Inhalation (Vaping/Smoking) THC levels in milk typically peak 1 to 2 hours after inhalation. Since plasma levels drop relatively quickly, a 4 to 6-hour waiting window before nursing may reduce the concentration an infant receives.

Ingestion (Edibles) The liver metabolizes ingested THC into 11-Hydroxy-THC. This metabolite is more potent and carries a longer half-life. Edibles can create unpredictable spikes in milk concentration that persist for hours, making it difficult to time feedings.

Topicals: A Potential Alternative

For relief from postpartum discomfort or muscle soreness, cannabinoid-infused topicals may offer a different approach.

• Systemic Absorption: High-quality topicals typically do not enter the bloodstream in significant quantities.
• Blood-Brain Barrier: Because they stay localized, they generally do not cross the blood-brain barrier or circulate into the mammary glands.
• Safety Profile: This approach supports physical recovery while minimizing infant exposure to psychoactive compounds.

Terpene Interaction and Reducing Load

For those seeking harm reduction, evaluating the total cannabinoid load is helpful. It is possible to support therapeutic goals—such as sleep or inflammation management—without relying on high-THC doses by leveraging specific terpenes.

• Myrcene: Often used for support during postpartum insomnia.
• Linalool: Modulates GABA and glutamate, which may provide anti-anxiety benefits without requiring high-THC cultivars.
• Beta-Caryophyllene: Targets CB2 receptors to manage inflammation without contributing significantly to the psychoactive load in milk.

The 2.5mg Threshold

Standard commercial doses (10mg) are often discouraged for breastfeeding parents. If you use cannabis for medicinal support, the technical standard for harm reduction involves a "microdose" of 1mg to 2.5mg. This may help maintain alertness and responsiveness while keeping the concentration in lipid-rich milk lower.

Monitoring Infant Milestones

If you use systemic cannabis, stay vigilant regarding your baby's development. Monitor these three physiological indicators:

1. Sedation: Watch for excessive lethargy or difficulty waking the baby for feeds.
2. Suckling Efficiency: A sudden weakening of the latch or reduced suction strength is a concern.
3. Motor Stagnation: Track milestones such as head control and reaching for objects. Research has suggested a possible link between milk-based THC exposure and delayed motor development by the 12-month mark. The 2018 Pediatrics study (Bertrand et al.) documented cannabinoid concentrations in breast milk; separate longitudinal research has examined developmental outcomes — speak with your pediatrician for the most current evidence.

The Limitations of "Pump and Dump"

For regular users, "pump and dump" is often ineffective. Because THC is sequestered in the fatty tissue of the breast, milk may be re-infused as it is produced. Waiting only benefits the infrequent, one-time user. For daily users, the infant may be exposed to a steady state of cannabinoids regardless of pumping schedules.

If you require support for sleep or anxiety, consider transitioning to CBD-dominant (Type III) cultivars or CBN. While CBD does transfer to milk, it lacks the specific binding affinity for CB1 receptors that may pose developmental risks to your infant.

---

Legal Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always seek the advice of a physician regarding a medical condition. Efficacy has not been confirmed by FDA-approved research. Check your local laws regarding cannabis and terpene use.

Sources

1. Bertrand KA, Hanan NJ, Honerkamp-Smith G, Best BM, Chambers CD. (2018). Marijuana use by breastfeeding mothers and cannabinoid concentrations in breast milk. Pediatrics. 142(3):e20181076. PubMed

2. Moss MJ, Bushlin I, Kazmier K, Hendrickson RG. (2021). Cannabis use and breastfeeding: a review of the evidence. Curr Opin Pediatr. 33(2):178-184. PubMed

3. Baker T, Datta P, Rewers-Felkins K, Thompson H, Kallem RR, Hale TW. (2018). Transfer of inhaled cannabis into human breast milk. Obstet Gynecol. 131(5):783-788. PubMed

4. Metz TD, Borgelt LM. (2018). Marijuana use in pregnancy and while breastfeeding. Obstet Gynecol. 132(5):1198-1210. PubMed